Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017;24(5):456-465.
doi: 10.2174/0929866524666170120095128.

Bispecific Antibodies (bsAbs): Promising Immunotherapeutic Agents for Cancer Therapy

Affiliations
Review

Bispecific Antibodies (bsAbs): Promising Immunotherapeutic Agents for Cancer Therapy

Deasmond O Acheampong et al. Protein Pept Lett. .

Abstract

Antibodies have become the preferred therapeutic treatment option for cancers. Antibody therapy is associated with low toxic profile and specific in its activity, unlike chemotherapy and radiotherapy. Types of tumor are known to express multiple receptors that cross-talk to activate perpetual growth, proliferation and metastasis, and inhibit apoptosis in such tumors. Bispecific antibodies (BsAbs) are therefore the preferred agent for the treatment of such cancers due to its unique characteristics. This review discusses up to date therapeutic potentials of BsAbs.

Keywords: Antibody; antitumor; bispecific antibody (BsAb); cancer therapy; diabody; immunotherapeutic agent.

Similar articles

See all similar articles

Cited by 2 articles

Substances

Feedback